Dark

NVS
Novartis AG - ADR
stock NYSE ADR

At Close

2/3/2023 4:00:01 PM EST

85.85USD-0.290%(-0.25)3,891,241

85.82Bid 85.84Ask 0.02Spread IEX

Pre-market

2/3/2023 9:23:30 AM EST

86.07USD-0.035%(-0.03)10

After-hours

2/3/2023 4:00:30 PM EST

85.85USD+0.012%(+0.01)0

Overview Option Chain HistoricalMore

open chart

Market Cap

206.359B

Headquarters

Basel, Basel Stadt, Switzerland

Industry

Drug Manufacturers-General

Last Dividend

2022-03-082.182

Last Split

2019-04-091.11607143for1

GSK ABT BMY JNJ PFE SNY MRK TEVA XLV

NVS Stats

Avg. Vol. 10 Day

2,446,987

Avg. Vol. 30 Day

2,247,212

Dividend Yield

3.769%

Dividend Rate (ttm)

3.325

Employees

108,000

Market Cap

206,359,469,484

Shares Out.

2,403,721,252

Float

2,048,553,850

P/E Ratio

9.73

EPS (ttm)

9.810

On/Off Exchange

69%/31%

6 Month Beta

0.39

1 Year Beta

0.40

2 Year Beta

0.39

3 Year Beta

0.55

52 Week Low

74.09

52 Week High

94.26

SMA50

91.01

SMA200

84.67

1 Week

-4.23%

1 Month

-5.45%

3 Month

+5.05%

6 Month

+0.33%

1 Year

-0.50%

2 Year

-5.17%

5 Year

+1.20%

Jan 31, 2022

04:51PM EST Amgen Reports In 8K Filing Co Entered Into Amendment No. 3 To Exclusive License & Collaboration Agreement With Novartis Benzinga

Jan 26, 2022

08:00AM EST Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announces the appointment of Cintia Piccina as Chief Commercial Officer effective January 31, 2022. GlobeNewswire Inc

Jan 18, 2022

04:25AM EST Molecular Partners Finalized License Agreement with Novartis for Ensovibep for COVID-19; Molecular Partners to Receive Milestone Payment of CHF150M, 22% Royalty on Ensovibep Sales in Relevant Territories Benzinga

01:26AM EST Molecular Partners AG (MOLN), a clinical-stage biotech company developing DARPin therapeutics, Tuesday said it has entered into a license agreement with Novartis AG (NVS), under which the Swiss drug major will in-license global rights to ensovibep from Molecular Partners. RTTNews

01:12AM EST Molecular Partners Finalizes License Deal With Novartis For Ensovibep For COVID-19 RTTNews

More News

Profile

Novartis AG is a Swiss-American multinational pharmaceutical corporation based in Basel, Switzerland and Cambridge, Massachusetts, United States. It is one of the largest pharmaceutical companies in the world.

NVS Stock Summary

Novartis AG - ADR (NYSE:NVS) stock price today is $85.85, and today's volume is 3,891,241. NVS is down -0.290% today. The 30 day average volume is 2,247,212. NVS market cap is 206.359B with 2,403,721,252 shares outstanding.

document.getElementById("vWtjy3").onerror = function(){this.style.display='none';}; .dark-mode .PMMvgW{ color: white; background-color: #333333; border: 2px solid white; }.light-mode .PMMvgW{ color: #333333; background-color: white; border: 2px solid #333333; }NVSNovartis AG - ADRstock NYSE ADR

NVS Stock Summary

NVS
Novartis AG - ADR
stock NYSE ADR